Table 3.
Adverse events
| Adverse event rate per 100 patient years | ||||||
|---|---|---|---|---|---|---|
| Class I obesity (30–34.9 kg m−2) | Class II obesity (35–39.9 kg m−2) | Class III obesity (≥40 kg m−2) | ||||
| Placebo (n = 91) | Semaglutide (n = 89) | Placebo (n = 83) | Semaglutide (n = 88) | Placebo (n = 92) | Semaglutide (n = 86) | |
| Serious adverse events | 53.7 | 32.2 | 39.0 | 18.4 | 56.7 | 20.4 |
| Deaths | 0.0 | 2.5 | 3.5 | 0.0 | 2.2 | 1.1 |
| Category of serious adverse event | ||||||
| Cardiac disorders | 19.7 | 7.4 | 9.5 | 1.2 | 18.9 | 1.1 |
| Infections and infestations | 3.3 | 3.7 | 13.0 | 2.3 | 8.9 | 0.0 |
| Gastrointestinal disorders | 3.3 | 2.5 | 0.0 | 4.6 | 5.6 | 3.4 |
| Nervous system disorders | 3.3 | 6.2 | 3.5 | 1.2 | 1.1 | 2.3 |
| Renal and urinary disorders | 1.1 | 3.7 | 1.2 | 1.2 | 4.4 | 3.4 |
| Respiratory, thoracic and mediastinal | 6.6 | 0.0 | 2.4 | 0.0 | 3.3 | 0.0 |
| Musculoskeletal and connective tissue | 1.1 | 0.0 | 1.2 | 3.5 | 3.3 | 2.3 |
| Injury, poisoning and procedural | 3.3 | 0.0 | 2.4 | 2.3 | 0.0 | 2.3 |
| Metabolism and nutrition disorders | 2.2 | 0.0 | 1.2 | 2.3 | 1.1 | 1.1 |
| Hepatobiliary disorders | 2.2 | 3.7 | 0.0 | 0.0 | 0.0 | 1.1 |
| General disorders and administration site | 0.0 | 0.0 | 1.2 | 0.0 | 2.2 | 1.1 |
| Neoplasms benign, malignant and unspecified | 1.1 | 0.0 | 1.2 | 0.0 | 1.1 | 1.1 |
| Serious adverse event leading to discontinuation | 4.4 | 5.0 | 1.2 | 1.2 | 2.2 | 2.3 |